For children aged 10 to 17 years, there are limited data on rosiglitazone as monotherapy (see sections 5.1 and 5.2).
Vähe on andmeid rosiglitasooni kasutamise kohta monoteraapiana 10... 17- aastastel lastel (vt lõigud 5. 1 ja 5. 2).